Renal effects of dapagliflozin in patients with type 2 diabetes

被引:47
|
作者
Thomas, Merlin C. [1 ]
机构
[1] Baker IDI Heart & Diabet Inst, 75 Commercial Rd, Melbourne, Vic 3004, Australia
关键词
dapagliflozin; diabetes; diabetic nephropathy; hyperfiltration; SGLT(2); inhibition;
D O I
10.1177/2042018814544153
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus was originally conceived as a renal disorder. In the last decade, however, there has been renewed interest in role of the kidney in the development and maintenance of high glucose levels. This has led to the development of novel agents to inhibit sodium glucose transporter-2 (SGLT(2)) as a means to better control glucose levels and at the same time augment calorie wasting and lower insulin, blood pressure and uric acid levels. Such actions, indirectly, may also have benefits for the prevention of diabetic complications including renal disease. However, there are also data to support the potential for direct renoprotective actions arising from inhibition of SGLT(2), including actions to attenuate diabetes-associated hyperfiltration and tubular hypertrophy, as well as reduce the tubular toxicity of glucose. Some studies have demonstrated significant reductions in albumin excretion in various experimental models, independent of its effects on blood pressure or glucose control. Although promising, such actions remain to be established by comprehensive clinical trials with a renal focus, many of which are currently in progress. This article reviews the clinical and experimental data pertaining to the renal effects of SGLT(2) inhibition with a particular focus on dapaglifozin.
引用
收藏
页码:53 / 61
页数:9
相关论文
共 50 条
  • [1] Effects of Dapagliflozin Therapy on Renal Hemodynamics in Type 2 Diabetes Patients
    Qin, Yuejuan
    Baskoy, Gozde
    Triplitt, Curtis L.
    Solis-Herrera, Carolina
    Adams, John M., III
    Defronzo, Ralph A.
    Cersosimo, Eugenio
    [J]. DIABETES, 2023, 72
  • [2] Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
    Hinnen, Deborah
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (03) : 92 - 102
  • [3] The effect of dapagliflozin on renal function in patients with type 2 diabetes
    Donald Elliott Kohan
    Paola Fioretto
    Kristina Johnsson
    Shamik Parikh
    Agata Ptaszynska
    Lisa Ying
    [J]. Journal of Nephrology, 2016, 29 : 391 - 400
  • [4] The effect of dapagliflozin on renal function in patients with type 2 diabetes
    Kohan, Donald Elliott
    Fioretto, Paola
    Johnsson, Kristina
    Parikh, Shamik
    Ptaszynska, Agata
    Ying, Lisa
    [J]. JOURNAL OF NEPHROLOGY, 2016, 29 (03) : 391 - 400
  • [5] Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes
    Iijima, Yasuhiro
    Nakayama, Masafumi
    Miwa, Takashi
    Yakou, Fumiyoshi
    Tomiyama, Hirofumi
    Shikuma, Junpei
    Ito, Rokuro
    Tanaka, Akihiko
    Manda, Naoki
    Odawara, Masato
    [J]. INTERNAL MEDICINE, 2023, 62 (05) : 681 - 688
  • [6] Dapagliflozin does not impact renal function in patients with type 2 diabetes
    Ptaszynska, A.
    Chalamandaris, A. -G.
    Sugg, J.
    Johnsson, K.
    Parikh, S.
    List, J. F.
    [J]. DIABETOLOGIA, 2012, 55 : S107 - S107
  • [7] Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients
    Baskoy, Gozde
    Qin, Yuejuan
    Cersosimo, Eugenio
    Solis-Herrera, Carolina
    Adams, John M., III
    Defronzo, Ralph A.
    Triplitt, Curtis L.
    [J]. DIABETES, 2023, 72
  • [8] Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes
    Fioretto, Paola
    Avogaro, Angelo
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (05) : 517 - 527
  • [9] Protective renal effect of dapagliflozin in type 2 diabetes
    Dobler, Gabriele
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 (01) : 17 - 18
  • [10] Effect of Dapagliflozin on renal protection in patients with uncontrolled type 2 diabetes mellitus
    张德园
    [J]. China Medical Abstracts (Internal Medicine), 2020, 37 (01) : 21 - 22